References


References


References


References


References

STARBRIGHT CD-ROM program for children and adolescents with cystic fibrosis. Journal of
Pediatric Psychology, 29, 259–267.

1668–1674.

childhood epilepsy. Archives of Disease in Childhood, 46, 386–388.

of Pediatric Psychology, 10, 1–14.

New York: Plenum.

What accounts for poor metabolic control in minority youths with diabetes? Annals
of Behavioral Medicine, 19 (Suppl.), S064.

observed family relationship quality and problem-solving skills with treatment adherence
in older children and adolescents with cystic fibrosis. Journal of Pediatric Psychology, 29,
343–353.


Effect of economic status on the use of house dust mite avoidance measures in asthmatic

J. E. Singer (Eds.), Handbook of health psychology (pp. 235–247). Mahwah, NJ: Lawrence
Erlbaum Associates.

pliance with a medication regimen: Parent interview, medication diary, unused medication

regimen compliance. Hospitals, 49, 85–89.

(1991). The process of smoking cessation: An analysis of precontemplation, contemplation,

ior: A comparison of process of change in cessation and maintenance. Addictive Behaviors, 7,
133–142.

medical practitioner’s role. New York: Pergamon.

Disney, F. A., Francis, A. B., Breese, B. B., Green, J. L., & Talpey, W. B. (1979). The use of cefaclor
in the treatment of beta-haemolytic streptococcal throat infections in children. Postgraduate
Medical Journal, 55, 50–52.

etin for treatment of anemia of chronic disease in children with Crohn’s disease. The Journal
of Pediatrics, 132, 155–159.

medical adherence from children with HIV and their adult caregivers. Journal of Pediatric

of an education programme on the self-management of aerosol and airway clearance treatments
for children with cystic fibrosis. Chronic Respiratory Disease, 3, 19–27.

31, 31–36.
References


References


References


Index

Note: The letters f and t following the locators refer to figures and tables respectively

A
Aaronson, N. K., 107, 112
Abadom, V., 23
ABA theory, see Applied behavior analytic (ABA) theory
Abetz, L., 30, 107
Abrams, E. J., 24, 25
Abshire, D. A., 153
Achenbach, T. M., 108, 110
Ackerson, L., 95
Ackloo, E., 152
Acute disease regimens
adherence rates
assessment criteria, example, 4
in pediatrics, 5r–6t
urine assays/pill counts, assessment to, 4
in pediatrics, adherence intervention studies, 148r–150t
Acute pediatric diseases, 147–151, 148r–150t, 177
Adams, C. D., 2, 3
Adesman, A. R., 39
Adherence
definitions, 1–2
by Haynes, 1
by WHO, 2
elements of
behavior/advice, concordance, 2
behavioral requirements, 1
‘extent,’ 2
health-care providers, role, 2
importance of, 184–185
intervention studies
acute pediatric diseases, 147–151
problems, types, 3–4
drug holidays, consequences, 3
nonadherence, unintentional/volitional, 3
rebound effect, drug toxicity, 3
rates
acute disease regimens, 4–7
chronic disease regimens, 7
“Adherence main effect,” 36
Adherence measures, comparative performance
electronic monitors/other measures of adherence in pediatric medicine, 95r–101t
Adlis, S. A., 9
Aggarwal, R., 24
“Agreed recommendations,” 2
Aiken, L. S., 36
Aims, assessment of adherence
evaluation of intervention efforts, 71
intervention selection
nature of adherence problems, 70–71
types of adherence problems,
examples, 70
prediction, 70
screening and diagnosis, 69–70
Aitchison, T. C., 98
Ajzen, I., 55, 56, 57
Akçay, F., 20, 24
Albin, R. W., 142
Aleksseev, L., 26
Algina, J., 103
Aligne, C. A., 118, 119
Allen, K. D., 142
Allergens, 50
Altemeier, W. A., 149
Altinkaynak, S., 24
Ambler, G. R., 24
Anand, V. K., 23
Anderson, B., 13
Anderson, B. J., 37, 40
Anderson, C. M., 37, 66
Anderson, H. A., 34
Anson, O., 19
Anti-inflammatory medication, 34, 50, 141
nonsteroidal, 129
oral, Naproxen, 66
Antiretroviral medications, 2, 112, 139, 181
Applied behavior analytic (ABA) theory, 63–67
appraisal
“cognitivist challenge” to ABA model, 65
clinical implications
polyarticular JRA, strategies to adherence, 66–67
14-year-old male with polyarticular JRA, example, 66
contingency-shaped and rule-governed behavior, 63
operant theory, effects on behavior, 63, 64f
description, 63–64
functional analysis, critical dimension of, 64
April, K. T., 26, 41
Apter, A. J., 94, 95
Arfken, C., 92
Arfken, C. L., 17
Aronson, N., 106
Asthma
mortality, effect of nonadherence, 34
patients, requirements
inhaled anti-inflammatory medication, 50
inhaled bronchodilator medication, 50
Athreya, B. H., 41, 107
“Attitudinal” theories, 57
Auslander, W. F., 37
Averbuch, M., 82
Avruskin, T. W., 37
B
Backes, J. M., 76
Baer, D. M., 63
Baker, S. A., 28
Baldassano, R. N., 21
Balson, P. M., 152
Balu, S., 35
Bandura, A., 48, 51, 52, 53, 54, 61, 65, 66
Bandura’s concept of self-efficacy, 48
Barabino, A., 19
Barakat, L. P., 29, 41
Barlow, D. H., 180, 183, 184
Barnard, M. U., 4, 35, 41, 65, 77, 102, 122, 140
Barrios, B. A., 69, 71, 103, 104
Barron, A., 42
Bartholomew, L. K., 158
Bartlett, S. J., 8, 39
Bass, J. W., 148
Bauman, L. J., 8, 34, 139
Baum, D., 153
Bazzigaluppi, E., 20
Beck, D. E., 29, 37, 38, 40, 172
Becker, M. H., 19, 48, 50, 53, 149
Beck, S., 77
Behavioral checklists, purpose of, 77
Behavioral intentions, factors, 56f
attitude towards behavior, 56
perceived behavioral control, 56
subjective norms, 56
Behavioral strategies for improving adherence, 127–140
adherence incentives, 129–134
negotiating and contracting for behavior change, 134f
token-system program, 130f–131f
discipline strategies, 135–137
skilled or effective discipline, 135
time-out handout, 135f–137f
parental monitoring and supervision, 127–129
parents of teenagers, 128
regimen-monitoring form, 128f
prompting adherence, 129
Hand-held PDA programs, 129
psychotherapeutic interventions, 138
self-management strategies, 138
cognitive and contemporary behavior, 138
problem-solving skills, 138
psychotherapeutic interventions, 138
treatments/diseases with positive/negative consequences, 139f
See also Improvement strategies of adherence
Beléndez, M., 165
Bellack, A. S., 79
Bell-Dolan, D. J., 79
Bell, G. L., 90
Belmont, J. M., 8, 9, 28, 182
Bender, B., 95
Bender, B. G., 8, 41
Benet, L. Z., 74
Berg, C. J., 8, 9
Berg, J. S., 35, 39
Bergman, A. B., 5, 7
Berkovitch, M., 82, 176
Berrien, V. M., 170
Bertakis, K. D., 148
Blackmore, A. M., 159
Blaschke, T., 2
Blaschke, T. F., 104
Bloom, B. R., 34
Blount, R. L., 50
Blowey, D. L., 30, 79, 96
Blue, J. W., 106
Blumenstock, G., 4
Bobrow, E. S., 37, 39, 40, 42, 49
Boccuti, L., 77
Boggs, S. R., 107, 172
Bolinger, M. E., 96
Bond, G. G., 36, 37, 40, 42, 49, 89
Bond, W. S., 84, 92, 102
Bonner, S., 153
Borch, R. F., 76
Borèus, L. O., 77
Bouter, L. M., 153
Bovaird, J. A., 30
Boyer, A., 177
Brackett, J., 13
Brackis-Cott, E., 24, 25
Braes, P. U., 157
Bransford, J. D., 85
Branstetter, A. D., 9, 39, 53
Brazeau, M., 6
Breeze, B. B., 5
Brewer, E. J., 26, 42
Brink, S., 53
Bronchodilator medication, 50, 51, 54, 134
Brooks, A. J., 40, 41, 42
Brooks-Gunn, J., 76
Brownbridge, G., 37, 39, 40, 41
Brownlee-Duffeck, M., 50, 89
Brown, S. J., 143, 161
Burge, D. A., 79
Burkhart, P. V., 153
Burroughs, T. E., 40
Bursch, B., 50
Bush, P. J., 48, 49
Buston, K. M., 42
Butz, A. M., 96
Buu, A., 107

C
Cadman, D., 108
Cairns, G. E., 11
Cairns, N. U., 11
Cameron, J., 11
Cantrill, J. A., 143
Carlino, P., 147, 149
Carlsten, K.-H., 7
Carney, R. M., 161
Carroll, M. S., 151
Carton, J. S., 172
Cary, J., 76
Casey, R., 10, 148
Catania, A. C., 53
Catto-Smith, A. G., 23
CD-ROM or web-based program for enhancing adherence, elements of, 143–145, 144
Celano, M., 9, 40, 42, 77
Chan, A., 24
Chan, D. S., 145, 154
Channell, S., 90
Charney, E., 5
Chasarlow, F., 10
CHBM, see The Children’s Health Belief Model (CHBM)
Cheang, M. S., 10
Chemlik, F., 97
Chesney, M. A., 36
The Children’s Health Belief Model (CHBM), 48, 49
caretaker, role of, 48, 49
study, factors used/limitations, 49
Christensen, N. K., 15
Christophersen, E. R., 27, 36, 69, 73, 84, 119, 149
Chronic disease regimens, 4, 7, 43, 61, 71, 102, 119, 121, 123, 130, 140, 151
adherence rates in pediatrics, 8t–31t
HIV/GI disorders, study, 7
medication/non-medication regimens, adherence rates, 7
Chronic pediatric diseases, 151–152, 153t–176t
insulin-dependent diabetes children’s regimen, 151–152
Chudziker, G. M., 5
Cipani, E., 135
Clark, N. M., 48, 57, 181
Cleemput, I., 35
Clinical implications of correlates, 43–45
disease-related correlates, 44
parental monitoring, importance, 43
patient/family correlates, 43–44
regimen-related correlates, 44–45
static/immutable variables, examples, 43
Clinically significant nonadherence (CSN), 183
Cluss, P. A., 9, 34, 76
Cobden, D., 35
Cognitive/self-mediated thought processes, 67
Competent functioning, 52
Contingency-shaped and rule-governed behavior, see Applied behavior analytic (ABA) theory
Contingency-shaped behavior operant processes, effects on behavior negative punishment/reinforcement, 63 positive punishment/reinforcement, 63
Controlled clinical trials (RCTs), 183
Corcoran, K. J., 54
Correlates of adherence
cautions
causal relationship development, conditions, 42
clinical implications, 43–45 disease-related correlates, 44 parental monitoring, importance, 43 patient/family correlates, 43–44 regimen-related correlates, 44–45 static/immutable variables, examples, 43
Coutts, J. A. P., 9, 79
Cox, C., 82
Cramer, J. A., 79, 82
Crandall, W. V., 22
Creer, T. L., 153
Crocker, L., 103
Croft, D. R., 119 “Cross-informant variance,” 108
CSN, see Clinically significant nonadherence (CSN)
Cuffari, C., 20, 23 “Culturally sensitive model,” 38
Cummings, K. M., 40
Cunningham, P. B., 171
Cuskey, W. R., 27, 37, 40
Cystic fibrosis (CF) application of SCT to, 54–55 medical regimen of 7-year-old female with, 54
Czajkowski, D. R., 12
Czajkowski, S. M., 36
D
Da Costa, I. G., 130, 154
Dahlström, B., 86
Dahms, W. T., 134
Daily Count Index (DCI), 104
Daschner, F., 5
Data interpretation, adherence measurement units of analysis/formulas
Daily Count Index (DCI), 104
Exact Daily Adherence (EAC), 105
Fraction of Doses (Fr), 104
Prescribed Intervals Method (PI), 105
Therapeutic Coverage (TC), 105
Davies, P., 23
Davies, W. H., 166
Davis, C. L., 89
Davis, C. M., 21
Davis, M. A., 143
Davis, T., 161
Dawes, R. M., 85
Dawson, K. P., 176
Day, A. S., 23
DCI, see Daily Count Index (DCI)
Deaton, A. V., 3
Deci, E. L., 65
Decisional balance, meaning, 59
DeCuir-Whalley, S., 11
DeGeest, S., 35
Delamater, A. M., 17, 89
DeLambo, K. E., 88
De la Sota, A., 156
Dell, R., 76
Demir, H., 20
Denson-Lino, J. M., 37
DeVellis, B. M., 52, 53
DeVellis, R. F., 52
Devries, J. M., 94
Diabetes, Type 1, 61–62
medical regimen of 16-year-old male with, 61–62
application of TTM to, 62
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 70
Dickey, F. F., 5
DiClemente, C. C., 58, 61
DiMatteo, M. R., 105
Dinakar, C., 2
Dischler, J., 35
Discipline strategies, 135–137
skilled or effective discipline, 135
time-out handout, 136–137
See also Improvement strategies of adherence
Disease and adherence/health outcomes assessment
adherence assessment, aim
intervention efforts, evaluation of, 71
intervention selection, 70–71
prediction, 70
screening and diagnosis, 69–70
adherence measurement,
issues/recommendations
clinical and treatment utility, 105–106
clinicians and researchers, role of, 102, 103, 104
data interpretation, 104–105
directness, 103
measurement standards, 103–104
reactivity, 102
representativeness, 102–103
assessment strategies, assets/liabilities
adherence measures, comparative performance, 94–102
assets/liabilities of adherence measures, 74–77
drug assays, 74–77
electronic monitors, 79–83
observation, 77–79
patient/parental reports, 86–94
pill counts, 83–84
provider estimates, 84–85
disease/health measures,
issues/recommendations
choice of informants, 108
generic vs. disease-specific measures, 109
psychometric standards,
see Psychometric standards of adherence
representativeness, 108–109
disease/health outcomes assessment, 106–107
patients, assessment
adherence monitoring, informants/assessors role, 73
patient/parent regimen-related behaviors, 73
training/quality control programs to informants, 73
target behaviors
guidelines for selection, see Target behaviors for assessing adherence, selection of
Disease-related correlates, 40–41
course, 40
duration, 40
perceived severity, 41
symptoms/disease severity, 40–41
Disney, F. A., 5
Doershuk, C. F., 135
Dohil, R., 20
Dolezal, C., 24, 25
Donithan, M., 96
Doughty, A., 97
Downs, J. A., 159
Drabman, R. S., 160
Dracup, K. A., 2
Dreyer, M. L., 2, 30
Drotar, D., 11, 16, 39, 73, 88, 111, 135, 139, 143, 145, 177
Drug assays
absorption of drugs
oral administration of drugs, effects, 74–75
assets/liabilities, 76–77
bioavailability of drug, factors affecting, 75
drug metabolism
enzymatic reactions, result of, 75
liver enzymes, role in, 75
elimination/excretion of drug by urination, 75
“Drug holiday,” 3
Drug-resistant microbes, 34
Drug(s)
absorption, 74–75
bioavailability of half-life, 75
Drug(s) (cont.)
steady state, 75
elimination/excretion
by urination, 75
metabolism
enzymatic reactions, result of, 75
plasma level, 3

DSM-IV, see The Diagnostic and Statistical
Manual of Mental Disorders
(DSM-IV)

D statistics, 152
See also Meta-analytic reviews
of adherence interventions

Duffy, C. M., 26
Dulberg, C., 5
Dunbar-Jacob, J. M., 153
Dunbar, J. M., 115

E
Eckel, E. M., 39
Eckernäss, S. A., 86
Educational strategies for improving
adherence, 116–121
content and objectives of education,
116–117
benefits of consistent adherence and
strategies, 117
information needs about the disease,
116–117
negative side effects of treatment, 117
factors to consider when developing health
education materials, 119
goals of education
knowing that and knowing how
(Ryle), 116
reference of patients with diabetes, 116
strategies, 117–120
handouts by drug companies, 119, 120
instructions for using a metered-dose
inhaler, 120
modeling and behavioral rehearsal,
120
ongoing process, 117
pamphlets and information on Web
sites, 118
verbal communication, 117–118
written communication and other
media, 118–119

Edwards, T. C., 107

Effect size (ES) estimate, 152
See also Meta-analytic reviews
of adherence interventions

Egleston, P. A., 185

Eidson, M., 17
Eisenberger, R. M., 65
Eiser, C., 107
Eisler, I., 31
El-Charr, G. M., 42
Electronic monitors
application of, 79
assets/liabilities, 80–83
See also Medication Event Monitoring
System (MEMS®)

Ellis, D. A., 40, 44, 161, 162
Ellison, R. S., 149
Enactive mastery, 55
Endres, R. K., 18
Eney, R. D., 9, 151, 154
Enhancement factors for self-efficacy
enactive mastery, 55
verbal persuasion, 55
vicarious experiences, 55
Epstein, L. H., 9, 34, 36, 76, 77, 151, 163
Epstein, R. S., 35
Erickson, M. T., 78, 79, 102
Ertokin, V., 20, 24
Espelage, D. L., 73, 88
Ettinger, R. B., 30, 33
Evers, K. E., 59
Exact Daily Adherence (EAC), 105

F
Faier-Routman, J., 111
Farkas, G. M., 77
Farley, J., 90, 98
Farley, J. J., 25
Farmer, K. C., 73
Faust, D., 85
Feinstein, A. R., 112
Feinstein, S., 30, 37, 40
Feldman, D. E., 26, 34, 37, 41
Feldman, H. I., 94
Feldman, W., 5
Fennell, R. S., 172
Ferguson, A. E., 98
Ferrus, S., 90
Festa, R. S., 10, 39
Fielding, D. M., 37, 39, 40, 41
Figueroa, J., 77
Fink, D., 149
Finkelstein, D., 13
Finley, R., 177
Finney, J. W., 69, 84, 149
Fireman, P., 9, 34, 153
Fisher, M., 55
Fisher, C. B., 143
Fivush, B. A., 30
Fletcher, R. H., 36, 110
Fletcher, S. W., 36
Flowers, N. T., 104
Fobil, J. N., 143
Follansbee, D., 37
Forbes, G. B., 76
Forbis, S., 118, 119
Forster, D., 143
Foster, S. L., 79
Foulkes, L. M., 172
Foye, H. R., 76
Fraction of Doses (Fr), 104
Francis, A. B., 5
Frazier, T., 177
Fredericks, E. M., 34
Freund, A., 37, 86
Frey, M., 44
Friday, G., 9, 34
Fried, A. L., 143
Friedman, I. M., 28, 38, 39
Fries, J. F., 107
Friman, P. C., 69, 71, 78, 142, 149
Fritz, G. K., 9
Fuchs, R., 53
Furth, S. L., 30

G
Galvis, S. A., 9, 34
Garber, J., 135
Garvie, P. A., 125, 171
Gastrointestinal (GI) disorders, 7
Gavin, L., 39, 151, 152
Gavin, L. A., 92
Geffken, G., 145
Geiss, S. K., 39
Gelfand, K., 145
Geller, R. J., 9, 77
Generic vs. disease-specific measures, 109
Gerber, M. A., 5
Gerich, J., 118
Gerson, A. C., 30, 39, 79
Gerstner, T. V., 10
Giannini, E. H., 26, 42
Gibbons, A., 34, 35
Gibson, N. A., 9, 98
GI disorders, see Gastrointestinal (GI) disorders
Gifford, E. V., 66
Gilbert, A., 169
Gilbert, B. O., 77
Gilbert, D. T., 85
Gilbert, J., 50
Gill, N., 112
Gill, T. M., 112
Ginsburg, C. M., 5
Glasgow, R. E., 39, 41, 49, 50, 166
Glauser, T. A., 3
Glazebrook, C., 143
Glowasky, A., 148
Goetchebeur, E., 36
Golden, M. P., 40
Goldring, J. M., 34
Goldsmith, D. P., 107
Goldstein, A., 6
Goldstein, D., 89
Goldstein, E. O., 9, 151, 154
Goldstein, G. L., 130
Goldsten, D., 7
Goodwin, D. A. J., 107
Gordis, L., 4, 6, 86, 94, 105, 112, 158
Graber, J. A., 76
Graham-Pole, J., 107
Graves, M. M., 177, 178, 179, 180
Gray, N. J., 143
Greco, P., 89
Greenan-Fowler, E., 170
Greenberg, M., 11
Green, B. F., 107
Greening, L., 13, 39
Green, J. L., 5
Green, L., 167
Greycloud, M. A., 149
Groopman, J., 85
Gross, A. M., 151, 163
Grossman, H. Y., 53
Grotz, W., 4
Grum, C. M., 181
Gudas, L. J., 36, 37, 38, 39, 41, 49, 84
Guerin, B., 50, 57
Guevara, J. P., 181

H
Hagopian, L. P., 159
Hains, A. A., 166
‘Half-life’ of drug, definition, 75
Halsey-Lyda, M., 145
Halternman, J. S., 185
Hammersley-Maercklein, G., 39
Hansen, C. A., 37
Harmon, W. E., 39
Harris, C. V., 106, 107, 110
Harris, M., 92
Hartman, A. L., 125
Hartman, C., 21
Haskard, K. B., 105
Hassall, E., 20
Hauser, S. T., 39, 53
Havermans, G., 53
Hawkins, R. M. F., 53
Hawkins, R. P., 66
Hayes, S. C., 53, 54, 63, 64, 105, 138
Hayford, J. R., 27, 41
Haynes, R. B., 1, 2, 152, 181
Haynes, S. M., 42
Haynes, S. N., 64, 142
Hazard, A., 28, 39, 41
HBM, see Health belief model (HBM)
Health belief model (HBM), 48–51
appraisal, 48–50
conceptual/methodological grounds, criticism on, 49–50
pediatric medical adherence, 49
clinical implications, 50–51
asthma, strategies to adherence, 50–51
See also Behavioral intentions, factors description, 48
variables
cues to action, 48
perceived barriers/benefits, 48
perceived severity/susceptibility, 48
See also The Children’s Health Belief Model (CHBM)
Health outcomes and adherence assessment, measurement issues
assessment, aims
intervention efforts, evaluation of, 71
intervention selection, 70–71
prediction, 70
screening and diagnosis, 69–70
assessment strategies, assets/liabilities adherence measures, comparative performance, 94–102
assets/liabilities of adherence measures, 74r
drug assays, 74–77
electronic monitors, 79–83
observation, 77–79
patient/parental reports, 86–94
pill counts, 83–84
provider estimates, 84–85
disease/health measures, issues/recommendations choice of informants, 108
generic vs. disease-specific measures, 109
psychometric standards,
see Psychometric standards of adherence
representativeness, 108–109
disease/health outcomes assessment, 106–107
measurement, issues/recommendations clinical and treatment utility, 105–106
clinicians and researchers, role of, 102, 103, 104
data interpretation, 104–105
reactivity, 102
representativeness, 102–103
patients, assessment of adherence monitoring, informants/assessors role, 73
patient/parent regimen-related behaviors, 73
training/quality control programs to informants, 73
target behaviors guidelines for selection, see Target behaviors for assessing adherence, selection of
Health-related quality of life (HRQOL), 106
core domains of, 107
Heath, K. V., 3
Heidgerken, A. D., 145
Hein, K., 76
Heisenberg Uncertainty Principle, 104
Heisenberg, W., 104
Hemoglobin A1C, 107
Hendele, L., 94
Hendry, L., 50
Henley, M., 39
Henness, D. M., 6
Hentinen, M., 13
Hermann, C., 79
Herrold, A. J., 40
Hersen, M., 79, 180
Hents, P. S., 90
Hines, S., 90
HIV, see Human immunodeficiency virus (HIV)
Hobbs, S. A., 12, 39
Hobson, D., 17
Hoekelman, R. A., 94
Hogg, R. S., 3
Ho, J., 13
Holmbeck, G. N., 90
Holmes, C. S., 37, 38, 39, 40
Index

Hommel, K. A., 21
Hommell, K. A., 145
Hook, R. J., 69
Hoppe, J. E., 4, 6
Horner, R. H., 64, 142
Horwitz, R. I., 36
Horwitz, S. M., 36
Houle, C. R., 48, 57
Hovell, 115
Howe, C. J., 164
Howell, C. T., 108
Howe, S., 107
HRQOL, see Health-related quality of life (HRQOL)
Human immunodeficiency virus (HIV)
  antiretroviral medications, 2
  lower adherence to antiretroviral drugs, 34
Hussar, D. A., 84, 92, 102
Hutchinson, S. J., 28
Huxtable, K., 167

I
Iannotti, R. J., 14, 48, 49
Ievers, C. E., 135
Ievers-Landis, C. E., 7, 73, 88
Improvement strategies of adherence
  behavioral strategies, 127–140
  educational strategies, 116–121
  individualizing interventions
  barriers adherence interview answer choices, 141f
  barriers to adherence, 140–141
  functional analysis, 142–143
  organizational strategies, 121–127
  technology-based interventions, 143–145
Incentives, 129–134
  negotiating and contracting for behavior change, 134f
  token-system program, 130f–131f
See also Improvement strategies of adherence
Ingersoll, G. M., 40
Insulin-dependent diabetes children’s regimen, 151–152
Interventions
  barriers, mentioned by JRA patient, 141
  barriers to adherence, 140–141
  CD-ROM or Web-based interventions, 143, 144–145, 144f
  functional analysis, 142–143
  steps for conducting, 142–143
  individualizing
  barriers adherence interview answer choices, 141f
  barriers to adherence, 140–141
  functional analysis, 142–143
See also Interventions
nature of adherence problems
  clinicians, role of, 71
  patients who overdose, 70
  patients who underdose, 70
  technology-based, 143–145
  barriers to be addressed, 143
  CD-ROM or Web-based interventions, 143
  telehealth, 145
Intervention studies on improving adherence to regimens
  acute pediatric diseases, 147–151,
    148f–150f
  chronic pediatric diseases, 151–152,
    153f–176t
  insulin-dependent diabetes children’s regimen, 151–152
  importance of adherence, 184–185
  meta-analytic reviews
    acute pediatric diseases, 177
    for adults, 152–177
    chronic pediatric diseases, 177–180
    conclusions from, 180–181
  studies targeting acute disease regimens in pediatrics, 148f–150f
  top ten ways to advance research, 181–184
See also Research on pediatric medical adherence, ten ways to advance
Israel, D. M., 20
Iyengar, S., 7

J
Jacobson, A. M., 7, 14, 15, 37, 38, 39, 40
James, C., 143
James, D. S., 34
Jamieson, A., 176
Janz, N. K., 48, 50
Jarrett, R. B., 105
Jarzembski, T., 33
Jenkins, S. C., 159
Jensen, S. A., 29, 38
Johanson, C. E., 74, 75, 77
Johnson, S., 58
Johnson, S. B., 37, 72, 77, 86, 93, 94, 102, 106, 107
Johnson, T., 22, 23
Johnston, J. M., 47, 69, 73, 77, 102, 103
Jónasson, G., 7, 9, 37
Jordon, S. S., 13
Joshi, A. V., 35
*Journal of Applied Behavior Analysis*, 65, 142
JRA, see Juvenile rheumatoid arthritis (JRA)
Judd, B. A., 94
Jue, S. G., 82
Julius, S. M., 94, 99
Jung, D. C., 37
Juniper, E. F., 107
Juvenile idiopathic arthritis
- lower adherence to anti-inflammatory medications, 34
Juvenile rheumatoid arthritis (JRA), 38

K
Kahana, S., 177, 178
Kamps, J. L., 155, 183
Kanani, R., 152
Kaplan, M., 156
Kaplan, R. M., 92, 106
Kapur, G., 23
Kasprzyk, K. D., 55
Kastrissios, H., 104, 152, 181
Kavanagh, T., 112
Kazak, A. E., 43
Kazdin, A. E., 65, 66, 79
Kelloway, J. S., 9, 37
Kendall, P. C., 138
Kennard, B. D., 10, 39
Kessler, J. H., 160
Kesteloot, K., 35
“Keyne” behaviors, 72
Kidder, D. P., 129
Kirpalani, H., 108
Klein, J. D., 143
Klein, R. B., 9
Klemp, S., 89
Klinnert, M. D., 9, 87, 92
Klover, R. V., 17
Kniker, W. T., 155

Knowing that and knowing how (Ryle), 116
Kodish, E., 11
Koeske, R., 19
Kofi, O. A., 143
Kohlenberg, B. S., 64
Koins-Mitchell, D., 10
Kolaèek, S., 21
Kolski, G. B., 10
Konishi, C., 13
Koocher, G. P., 36
Kopel, S. J., 9, 10
Koren, G., 11, 79
Kovaes, M., 7, 15, 37, 39, 40

Kramer, J. C., 39
Krasner, L., 47
Kratochwill, T. R., 71
Krawiecki, N., 28
Krishnani, N., 24
Krishna, S., 143
Kruse, W., 79
Kuhn, T. S., 67
Kulik, J. A., 147, 149
Kumar, P. J., 21
Kumar, V. S., 164
Kurtin, P. S., 30, 39
Kuzmina, N., 26
Kvien, T. K., 27
Kyngas, H., 13

L
Labay, L., 50
Laffel, L., 13
Laffel, L. M., 164
Laffel, L. M. B., 164
La Greca, A. M., 37, 38, 39, 40, 43, 89, 151
Lamparski, D., 19
Lancaster, D., 11
Landgraf, J. M., 30, 107
Lansky, S. B., 11, 38
Lanzkowsky, P., 10
Lask, B., 31
Lau, R. C. W., 11, 79
Lavigne, J. V., 111
Lawson, M. L., 165
LeBaron, S., 155
Lee, D., 23
Lee, P., 58
Lee, W. C., 35
Lehane, E., 3
Lemanek, K., 130
Lennard, L., 11
Lensing, S., 125
Le Souef, P. N., 159
Leventhal, J. M., 139
Lewandowski, A., 39
Lewis, C. E., 156
Lewis, M. A., 156
Ley, P., 157
Lilienfeld, A. M., 6
Lilleyman, J. S., 11
Lindsley, C. B., 27, 28, 64, 73
Lipsey, M. W., 152
Liptak, G. S., 147
Litt, I. F., 27, 37, 38, 40
Liver enzymes, 75
- structure/functioning, impact on drug metabolism, 75
Index

Logan, D., 50
Lorenz, R. A., 15, 37, 77
Lovell, D. J., 42, 129
Lowe, K., 77, 165
Lowman, J. T., 11
Lucas, D. O., 125
Ludwig, S., 148
Lutfey, K. E., 1
Lutz, C. N., 10
Lutzker, J. R., 77, 165

M
MacKenzie, R., 6
Mackner, L. M., 22, 160
Mack, G., 3
Mack, B. J., 82
Mack, J. K., 4
Mack, W., 5
Mack, C. D., 118, 119
Mack, S., 25, 34
Mack, E. J., 69, 71, 77, 78, 79
Mason, B. J., 82
Mattern, J. M., 6, 158
Marks, M. I., 6
Maro, A., 156
Marshall, G. D., 115
Martin, F., 149
Martin, S., 25, 34
Mash, E. J., 69, 71, 77, 78, 79
Mason, B. J., 82
Matsui, D., 11, 42, 79
Matsuyama, J. R., 82
Mattar, M. E., 5
Mattar, M. F., 4, 6, 150
McCarty, G., 3
McCarty, J. M., 4
McCaughy, K. D., 39, 41, 42, 49, 166
McCormick, M. C., 10, 41
McDonald, H. P., 177
McGrath, P. A., 108
McGuigan, K. A., 35
McKay, K., 170
McKeever, L. C., 150
McKibben, K. A., 152
McLinn, S. E., 4, 6
McPherson, A. C., 143
McQuaid, E. L., 9, 10, 37, 38, 39, 43, 79, 87, 92
MDI, see Metered dose inhaler (MDI)
Meade, C. D., 118, 119
Measurement issues, adherence and health outcomes
assessment of adherence
intervention efforts, evaluation of, 71
intervention selection, 70–71
prediction, 70
screening and diagnosis, 69–70
assessment strategies, assets/liabilities
adherence measures, comparative performance, 94–102
assets/liabilities of adherence measures, 74r
drug assays, 74–77
electronic monitors, 79–83
observation, 77–79
patient/parental reports, 86–94
pill counts, 83–84
provider estimates, 84–85
generic methodological issues/recommendations
clinical and treatment utility, 105–106
clinicians and researchers, role of, 102, 103, 104
data interpretation, 104–105
directness, 103
measurement standards, 103–104
reactivity, 102
representativeness, 102–103
health measures, issues/recommendations
choice of informants, 108
generic vs. disease-specific measures, 109
psychometric standards,
see Psychometric standards of adherence
representativeness, 108–109
health outcomes assessment, 106–107
patients, assessment
adherence monitoring, informants/assessors role, 73
patient/parent regimen-related behaviors, 73
training/quality control programs to informants, 73
Measurement issues (cont.)
  target behaviors
  guidelines for selection, see Target behaviors for assessing adherence, selection of
  Med, C., 4
  Medical practice, culture of, 3
Medication Event Monitoring System (MEMS®)
  components of
    communicator module, 79
    monitor, 79
  example of data from, 81f
  Meehl, P. E., 85
  Meermann, R., 3
  Meichenbaum, D., 65
  Melancon, S. M., 64
  Meleis, A. I., 2
  Mellins, C. A., 24, 25
  Mellis, C. M., 157
  Memory devices, 4
  MEMS® SmartCap, 80
  MEMS® TrackCap, 79
  Méndez, F. J., 165
  Messer, M. A., 107
Meta-analytic reviews of adherence interventions
  acute pediatric diseases, 177
  for adults, 152–177
  chronic pediatric diseases, 177–180
  conclusions from, 180–181
Metered dose inhaler (MDI), 77
  checklist, 78f
  Mikkelsen, T., 164
  Milgrom, H., 95, 101
  Miller, J. P., 37
  Miller, S. T., 160
  Miller, V. A., 16, 39
  Millstein, S. G., 50
  Mitchell, J. R., 74
  Mitchell, W. G., 28
Model(s), see individual
  Modi, A. C., 3, 7, 12, 28, 40, 50, 79, 87, 92, 100, 107, 127, 140, 141, 145
  Mohindra, S., 24
  Moll, G., 13
  Momy, J., 5
  Montaner, J. S. G., 3
  Montañø, D. E., 55, 57
  Mora, S., 22
  Morey, L., 85
  Morita, D. A., 3
  Morris, E. K., 65, 66
  Morse, E. V., 152
  Morse, R., 107
  Mowinckel, P., 7
  Muir, A., 145
  Murphy, M. S., 22, 23
  Murray, C. J. L., 34
  Musk, A., 90
  Myers, R. S., 61

N
  Naar-King, S., 17, 37, 39, 44, 92, 171
  Nagelkerke, A. F., 157
  Naidoo, D., 23
  Naproxen, 66
  Narayan, S., 23
  Nazarian, L. F., 147
  Nelson, R. O., 105
  Neu, A. M., 30
  New, A., 19
  Newacheck, P. W., 34
  The “new gold standard,” see Electronic monitors
  Nightingale, E. O., 50
  Nock, M. K., 180
Nonadherence
  consequences, 35–36
    active/placebo medications, adherence effects, 35–36
    “adherence main effect,” 36
    clinical decisions, 35
  diagnosis of, 70
  health/well-being effects, 33–34
    African-American/Caucasian children, asthma-related death rates, 34
    anti-inflammatory medications, 34
    antiretroviral drugs, 34
    asthma in children/adolescents, 34
    immunosuppressive drugs, 33
    living/dead donor kidney transplantations, survival rates, 33
    microbial organisms, ‘inoculation’ of, 34
    tuberculosis reemergence, 34
    medical care, cost-effectiveness of, 34–35
    higher adherence, lower disease-related medical costs, 35
    pharmacokinetics, negative impact on, 36
    risk profile, 42–43
    unintentional, 3
    memory devices for patients with, 4
    volitional, 3
    medication side effects, 3
“Noncompliance with Treatment,” code, 70
Nonsteroidal anti-inflammatory medications (NSAIDS), 80
Norcross, J. C., 58
Noyce, P. R., 143
NSAIDS, see Nonsteroidal anti-inflammatory medications (NSAIDS)

O
O Ailin, A., 199
Oakley, M. G., 153
O’Brien, W. H., 64, 141
Obrosky, D. S., 7
O’Callaghan, A., 23
O’Connor, R. D., 37
O’Donohue, W., 47
Oermann, M. H., 118, 119
Ohene-Frempong, K., 29
O’Leary, A., 52, 53
Oliva-Hemker, M. M., 23
Oliver, M. R., 23
Olivieri, N. F., 29, 79, 101
Olson, N. Y., 28
O’Neill, R. E., 142
Ooi, C. Y., 23
Opipari, L. C., 92, 160
Oral corticosteroids, 54
Oral pancreatic enzyme replacement, 54
Organizational strategies for improving adherence, 121–127
consumer-friendly clinical settings, 121–122
increasing accessibility to health care, 121
contact with social service agencies, 121
outreach clinics, 121
increasing provider supervision, 122–123, 123 f–124 f
clinic visits/follow-up, 122
“report line” or phone number, 122
written treatment plan, 123 f–124 f
side effects of regimens minimize side effects, 125
simplifying and minimizing negative side effects of regimens
oral liquid medications, 125
pill-swallowing protocol used for children with cystic fibrosis, 126t–127t
reducing complexity, 125
tailoring regimens to patients’ lifestyles/schedules, 125
See also Improvement strategies of adherence
Orrbine, E., 165
Orr, D. P., 40
O’Shaughnessy, M. V., 3
Osterberg, L., 2
Ostosh, L., 118

P
Page, E. G., 151
Pui, A. L. H., 11
Palermo, T. M., 86, 107, 183
Pulmer-Shevlin, N., 35
Parcel, G. S., 54
Parental monitoring and supervision, 127–129
parents of teenagers, 128
regimen-monitoring form, 128 f
Park, D. C., 129
Parker, C. C., 38
Parks, B. R., 38
Parton, E., 166
Pashos, C. L., 35
Passero, M. A., 13, 41
Patient/family correlates, 37–40
adherence correlates to medical regimens, 37–40
barriers, 40
demographics, 37
family adjustment and coping, 39–40
knowledge, 38
parental involvement/monitoring, 40
patient adjustment and coping, 38–39
race, 38
SES, 37–38
barriers, 40
demographics, 37
family adjustment and coping, 39–40
knowledge, 38
parental involvement/monitoring, 40
patient adjustment and coping, 38–39
patient gender, correlate of adherence, 37
race, 38
SES and family composition, 37–38
Patient/parental reports
assessment strategy, assets/liabilities, 92–94
daily diaries, 86
global ratings, 86
structured interviews and questionnaires, 86
reliability/validity and self-report measures of adherence, 87t–91t
Patino, A. M., 17, 37, 38, 49
Paton, J. Y., 9, 98
Patrick, D. L., 107
Problems of adherence
  types/nature of, 70–71
Prochaska, J. O., 58, 59, 60, 61, 62
Prompting adherence, 129
  Hand-held PDA programs, 129
Psychometric standards of adherence
  clinical feasibility, utility, and relevance,
  111–112
  limiting “physiogenic bias,” 110–111
Psychotherapeutic interventions, 138
Psychotherapy, 58, 59
Purviance, M. R., 64, 73

Q
Quittner, A. L., 7, 40, 50, 73, 79, 87, 88, 91, 92, 93, 100, 102, 107, 123, 127, 140, 141, 143, 160

R
Rabinovich, M., 6
Rachelefsky, G., 156
Radius, S. M., 10, 36, 37, 41, 42, 49
Raina, J., 35
Rai, S. N., 125
Rand, C., 95
Rand, C. S., 76, 79, 80, 83, 92, 93, 102
Rapoff, M. A., 4, 7, 8, 9, 27, 28, 36, 37, 40, 41, 63, 64, 65, 69, 73, 77, 79, 84, 86, 102, 117, 119, 121, 122, 130, 132, 136, 138, 140, 142, 149, 151, 173, 174, 177, 180, 182, 183, 184
Rashid, M., 23
Ratner, P., 155
Rayens, M. K., 153
RCTs, see Controlled clinical trials (RCTs)
Readability of written material
  formulas for calculating, 119
  See also Educational strategies for improving adherence
Redding, C. A., 59
Reddington, C., 25, 34
Regimen-related correlates, 41–42
  adherence correlates to medical regimens,
  41–42
  costs, 41
  efficacy, 42
  side effects, 41–42
  type and complexity, 41
Reimers, S., 27
Reindenberg, B. E., 4
Remor, B., 13
Rescorla, L. A., 110
Research on pediatric medical adherence,
  tenways to advance, 181–184

PI, see Prescribed Intervals Method (PI)
Piaget’s theory, 60
Pichert, J. W., 15
Pichichero, M. E., 4, 6
Pieper, K. B., 64, 73, 83, 130, 173
Pill counts, 83–84
  assets/liabilities, 83–84
Plaquenil, antimalarial drug, 57
Pless, I. B., 139
Plienes, A. J., 160
Pollock, D. J., 82
Polyarticular JRA, 66
  application of ABA theory to, 66–67
  medical regimen of 14-year-old male
  with, 66
Pontious, S. L., 40
Pool, R., 155
Poppen, R. L., 64
Popper, K. R., 47
Portnoy, J. M., 2
Powell, C., 170
Powers, S. W., 159
Prednisone, corticosteroid, 57
Prescribed Intervals Method (PI), 105
conduct multisite/randomized controlled intervention trials, 184
develop electronic monitor measures, 183
develop practical measures of disease activity and quality of life, 183
develop promotion strategies and ways to deliver interventions, 184
develop self-report measures, 182–183
develop standard scores/cut points for classifying people, 181
make theories relevant to pediatrics, 181–182
prevention of anticipated declines over time, 183
settle on standard definition, 181
use of single-subject design methodology, 183

Reynolds, E., 170
Reynolds, L. A., 77
Richards, M. E., 40
Richardson, C., 165
Richardson, P., 163
Rieder, M. J., 42
Riegler, H. C., 63
Riekert, K., 92
Riekert, K. A., 79, 80
Riley, A. W., 107
Ritterband, L. M., 143
Roberts, C. M., 159
Roberts, G. M., 139
Roberts, M. C., 43, 119, 177, 180
Rock, D. L., 85
Rode, C. A., 107
Rodewald, L. E., 76
Rodrigues, A. F., 23
Rodrigues, W. J., 6
Rohay, J., 153
Rosas, A., 37
Rosen, B., 148
Rosenbaum, P., 108
Rosenberg, A., 27
Rosen, C. S., 61
Rosen, D., 11
Rosenstock, I. M., 48, 50, 53
Rosenthal, R., 152
Ross, C. K., 27, 41
Roter, D. L., 177, 180
Roth, D. L., 61
Roth, H. P., 74, 82
Rounds, K. A., 151
Rowbotham, M. C., 113
Royle, M., 24
Rubin, D. H., 144, 156
Rubin, L. G., 42
Rubio, A., 82
Rudd, P., 76, 77, 81, 83, 84, 93, 102
Ruggiero, L., 59, 61, 62
Rule-governed behavior, 63
problems/limitations, 64
Ryan, R. M., 65
Ryder, C., 92
Ryle, G., 116
Ryle, Gilbert (British philosopher), 116

S
Saadah, O. I., 23
Sahota, N., 152
Salazar, J. C., 170
Salomon, J., 13
Sanchez, J., 17
Santiago, J. V., 37, 40
Sanz, E. J., 2
Saputo, M., 150
Satin, W., 151
Schafer, L. C., 39, 41, 166
Schechter, K., 161
Scheier, L. M., 28
Schantag, J. J., 76, 77
Schlösser, M., 53
Schmidt, L. E., 17
Scholten, R. J., 157
Schwankovsky, L., 50
Schwartz-Lookinland, S., 150
Schwartz, R. H., 6
Schwarzer, R., 53
Schweitzer, J. B., 172
Scotti, J. R., 66
Screening
process of, 69
tool for adherence assessment, 69
SCT, see Social cognitive theory (SCT)
Sculerati, N., 6
Seale, J. P., 157
Secord, E., 171
Seid, M., 107
Seidman, L., 20
Selbmann, H., 4
Self-efficacy
conceptual/methodological grounds, criticism on, 53
enhancement, factors for, 55
health-related behaviors, predictor of, 52, 53
illness-specific scales for children/adolescents, 53
influence on health, pathways, 52
Self-efficacy (cont.)
judgments/outcome expectations, 52
person–environment interactions,
role in, 53
sources, 52
theory, 53
Self-management strategies, 138
cognitive and contemporary
behavior, 138
problem-solving skills, 138
psychotherapeutic interventions, 138
treatments/diseases with positive/negative
consequences, 139

See also Improvement strategies of
adherence

Selimoglobin, A., 20
Selimoglu, M. A., 24
Sergis-Davenport, E., 77, 170
Serrano-Ikkos, E., 31, 37, 38
SES, see Socioeconomic status (SES)
Sesselberg, T. S., 143
Shaw, J., 157
Sheeran, P., 57
Sheiner, L. B., 74
Shellmer, D. A., 83
Shemesh, E., 31, 38, 39, 40
Sherman, J. M., 94
Shingadia, D., 171
Siller, J., 37
Silverman, A. H., 166
Silverstein, J., 37, 77, 86
Simmons, F. E. R., 10
Simon, H. J., 92
Simon, P. M., 152
Simons, L. E., 50
Singer, J., 3
Singh, G., 107
Singh, J., 118, 119
Skinner, B. F., 63, 65, 66
Skyler, J. S., 37, 151
Slack, M. K., 40, 41, 42
SLE, see Systemic lupus
erythematosus (SLE)

Sleasman, J. W., 25
Sly, R. M., 34
Smith, A. W., 36
Smith, C. F., 118, 119
Smith, M., 34
Smith, N. A., 157
Smith, S. D., 11, 37
Smith-Whitley, K., 29
Smyth, A., 144
Smyth, A. R., 94

Snodgrass, S. R., 38
Snyder, C. R., 8
Snyder, J., 167
Social cognitive theory (SCT)
appraisal, 52–54
self-efficacy theory, criticism, 53
clinical implications, 54–55
CF, strategies to adherence, 54
clinicians, outcome expectancies, 55
7-year-old female with CF, example, 54
description, 51–52
adherence tasks, challenges faced by
children/adolescents, 52
self-efficacy, pathways,
see Self-efficacy
proposed/promoted by Albert Bandura, 51
Socioeconomic status (SES), 37–38
Socolar, R., 135
Sokol, M. C., 35
Somerville, S. C., 36
Sood, M., 22
Spangler, D. L., 151
Spergel, J., 50
Spieth, L. E., 106, 107, 110
Sprague, J. R., 142
Srivastava, A., 24
Stack, C. M., 143
Standards, adherence
accuracy, 103
reliability, 103
of interview/observational
measures, 103
validity, 103
Starfield, B., 107
Stark, L., 183, 184
Stark, L. J., 43, 151, 160, 169, 175
Starlight Foundation asthma program, “Quest
for the Code,” 144
Starr, M., 101
Steele, R. G., 30
Stein, R. E. K., 111
Stemminger, M. M., 41
Stern, R. S., 135
Stevens, B., 112
Stewart, S. M., 18, 37
Stiesmeyer, J., 156
Stinson, J. N., 112
Stoppelbein, L., 13
Storey, K., 142
Stork, P. P., 86
Strategies for assessment of adherence
adherence measures, comparative
performance, 94–102
assets/liabilities of adherence measures, 74–77

drug assays, 74–77
electronic monitors, 79–83
observation, 77–79
patient/parental reports, 86–94
pill counts, 83–84
provider estimates, 84–85
Stratman, A. C., 30
Strecher, V. J., 48, 50, 53
Strickland, D. E., 110
Stroebe, M. S., 50, 57
Stroebe, W., 50, 57
Strosahl, K. D., 66
Stuber, M., 34
Sturkey, P., 71, 72, 142
Swales, T., 89
Systemic lupus erythematosus (SLE), 57
medical regimen of 15-year-old female with, 57
application of TRA/PB to, 58

T
Takiya, L., 177
Talpey, W. B., 5
Tamaroff, M. H., 10, 39, 49
Taplin, S. H., 55
Target behaviors for assessing adherence, selection of

guidelines
baseline all behaviors, 71–72
critical or “keystone” behaviors, 72
easy to change behaviors, 73
problematic or disturbing behaviors, 72

Taylor, W. R., 34
Tebbi, C. K., 7, 11, 37, 38, 40
Technology-based interventions, 143–145

See also Improvement strategies of adherence
Templin, T. N., 44
Tepper, V., 90
Tepper, V. J., 25
Terdal, L. G., 69, 71, 78, 79
Theories

ABA theory, 63–67
clinicians, reasons for acceptance of, 47
definition, 47
HBM, 48–51
researchers, impact on, 47
SCT, 51–55
TRA/PB, 55–58
TTM, 58–62
See also individual

Theory of reasoned action/planned behaviour (TRA/PB), 56–f

appraisal, 57
clinical implications, 57–58
SLE, strategies to adherence, 58
15-year-old female with SLE, example, 57
description, 55–56
attitude, prediction of behavioral outcomes, 55–56
behavioral intentions, factors, 56

Theory of Reasoned Action (TRA), 55
Therapeutic Coverage (TC), 105
Thomas, A. M., 89, 138
Thomas, J., 86
Thompson, R. E., 23, 96
Thompson, R. H., 159
Time-out handout, 136–f–137 f

See also Educational strategies for improving adherence

Tinkelman, D. G., 10, 151, 157
Todd, J. T., 65, 66
Toll, D., 125
Tommasini, A., 24
Topolski, T. D., 107
Tor, M., 94
Tourangeau, R., 93
Transplant failures
lower adherence to immunosuppressive drugs, 33

Transtheoretical model (TTM)
appraisal, 59–61
TTM stages, criticism, 61
behavioral processes of change, types
cognitive/self-mediated thought processes, 67
environmental contingencies, 67
behavioral stages of change
cognitive self-regulatory systems of psychotherapy, applied to, 59
"transtheoretical," origin of term, 59
Transtheoretical model (TTM) (cont.)
  dimensions of, 60
  processes of change, 59
  health-related behaviors, 59
TRA/PB, see Theory of reasoned action/planned behaviour
  (TRA/PB)
Triadic reciprocal causation model, see Social cognitive theory (SCT)
Trueworthy, R. C., 11
Tuberculosis, reemergence
  adherence failures, effects, 34
Tucker, C. M., 31, 38, 40, 91
Türken, Y., 20
Turk, D. C., 65
Type 1 diabetes, 61–62
  medical regimen of 16-year-old male with,
  61–62
  application of TTM to, 62
U
Urquhart, J., 3, 35, 79, 80, 82
V
Valenzuela, D., 86
Vandereycken, W., 3
Vanderpool, G. E., 151
Van Dyke, R. B., 25, 41, 90
Van Es, S. M., 40, 42, 157
Van Slyke, D. A., 135
Varasteh, L. T., 8
Variables that predict adherence
  cues to action, 48
  to medical regimens
    clinicians, role of, 67
    perceived barriers/benefits, 48
    perceived severity/susceptibility, 48
Varni, J. W., 65, 77, 107, 112, 169, 170
Vedanarayanan, V. V., 38
Verbally controlled (rule-governed) behavior, see Self-efficacy
Verbal persuasion
  ‘pep talks,’ 55
Verbrugge, R. R., 35
Vrijens, B., 36
W
Wadsworth, L. D., 20
Wagner, D. J., 35
Wagner, E. H., 36
Walco, G. A., 39
Walders, N., 9, 10, 37, 79
Walker, L. S., 135
Wallander, J. L., 43, 65
Ware, J. E., 107
Warzak, W. J., 142
Watroux, M., 107
Webb, T. L., 57
Weber, E., 79
Wehlou, K., 42
Weintraub, M., 82
Weizman, Z., 19
Wells, J. A., 110
Wentzell, K. J., 164
Werner, R. J., 5, 7
Westman, E., 24
White-coat compliance, 3
Whitehead, B., 31
Wicker, A. W., 47
Wiebe, D. J., 18, 40
Wiener, L., 92
Wildman, B. G., 78, 79, 102
Williams, P. L., 25, 39
Williams, R., 150
Williams, S. L., 105
Willies-Jaco, L. J., 37
Wilson, D. B., 152
Wilson, D. P., 18
Wilson, K. G., 53, 54, 66
Wilson, N. W., 37
Wing, R. R., 18, 19, 77
Winnick, S., 125
Winter, M. E., 74, 75, 76, 77
Wise, R. A., 76, 83, 93, 102
Wishner, W. J., 1
Wolf, F. M., 181
Wood, L. V., 92
Wood, P. R., 10
Wood, S. F., 42
Wu, Y. P., 119, 177, 180
Wyatt, R. A., 9
Wynn, K. S., 39
Wyplj, D., 36
Wysocki, T., 39, 43, 89, 151, 152, 167, 168
Y
Yachha, S. K., 24
Yaffe, S. J., 4
Yamada, J., 112
Yang, M. C. K., 143
Yao, X., 177
Yoman, J., 64, 142
Z
Zacharin, M., 23
Zaleski, S., 118
Zeevi, N., 19
Zeiger, R., 50
Zelikovsky, N., 50, 83
Zeltzer, L. K., 155
Zevon, M. A., 40
Zhang, M., 153
Zifferblatt, S. M., 63

“Ziggy Theorem,” 106
Zigo, M. A., 151
Ziman, R., 9
Zora, J. A., 10
Zunzunegui, M. V., 26